» Articles » PMID: 24464841

Inhibitory Activities of Trichostatin a in U87 Glioblastoma Cells and Tumorsphere-derived Cells

Abstract

Epigenetic alterations have been increasingly implicated in glioblastoma (GBM) pathogenesis, and epigenetic modulators including histone deacetylase inhibitors (HDACis) have been investigated as candidate therapies. GBMs are proposed to contain a subpopulation of glioblastoma stem cells (GSCs) that sustain tumor progression and therapeutic resistance and can form tumorspheres in culture. Here, we investigate the effects of the HDACi trichostatin A (TSA) in U87 GBM cultures and tumorsphere-derived cells. Using approaches that include a novel method to measure tumorsphere sizes and the area covered by spheres in GBM cultures, as well as a nuclear morphometric analysis, we show that TSA reduced proliferation and colony sizes, led to G2/M arrest, induced alterations in nuclear morphology consistent with cell senescence, and increased the protein content of GFAP, but did not affect migration, in cultured human U87 GBM cells. In cells expanded in tumorsphere assays, TSA reduced sphere formation and induced neuron-like morphological changes. The expression of stemness markers in these cells was detected by reverse transcriptase polymerase chain reaction. These findings indicate that HDACis can inhibit proliferation, survival, and tumorsphere formation, and promote differentiation of U87 GBM cells, providing further evidence for the development of HDACis as potential therapeutics against GBM.

Citing Articles

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy.

Everix L, Seane E, Ebenhan T, Goethals I, Bolcaen J Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259375 PMC: 9967489. DOI: 10.3390/ph16020227.


Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review.

Bouyahya A, El Omari N, Bakha M, Aanniz T, El Menyiy N, El Hachlafi N Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297347 PMC: 9612318. DOI: 10.3390/ph15101235.


Molecular Mechanisms of Vascular Damage During Lung Injury.

Ramos R, Adam A Adv Exp Med Biol. 2021; 1304:95-107.

PMID: 34019265 PMC: 8223730. DOI: 10.1007/978-3-030-68748-9_6.


Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells.

Buendia Duque M, Pinheiro K, Thomaz A, da Silva C, Freire N, Brunetto A J Mol Neurosci. 2019; 68(1):49-57.

PMID: 30887411 DOI: 10.1007/s12031-019-01280-5.


Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [F]TFAHA.

Laws M, Bonomi R, Kamal S, Gelovani D, Llaniguez J, Potukutchi S Sci Rep. 2019; 9(1):3595.

PMID: 30837601 PMC: 6401080. DOI: 10.1038/s41598-019-40054-2.


References
1.
Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R . Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res. 2012; 32(7):2407-13. View

2.
Foltz G, Yoon J, Lee H, Ma L, Tian Q, Hood L . Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme. Genes Cancer. 2011; 1(1):81-90. PMC: 3092177. DOI: 10.1177/1947601909356103. View

3.
Yoshida M, Horinouchi S . Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann N Y Acad Sci. 2000; 886:23-36. DOI: 10.1111/j.1749-6632.1999.tb09397.x. View

4.
Egler V, Korur S, Failly M, Boulay J, Imber R, Lino M . Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res. 2008; 14(10):3132-40. DOI: 10.1158/1078-0432.CCR-07-4182. View

5.
Berendsen S, Broekman M, Seute T, Snijders T, van Es C, de Vos F . Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. Expert Opin Investig Drugs. 2012; 21(9):1391-415. DOI: 10.1517/13543784.2012.694425. View